4 results on '"Khurram Jamil"'
Search Results
2. Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease
- Author
-
Miriam B. Vos, Lara Dimick-Santos, Ruby Mehta, Stephanie O. Omokaro, Johannes Taminiau, Elmer Schabel, David E. Kleiner, Peter Szitanyi, Piotr Socha, Jeffrey B. Schwimmer, Stephanie Noviello, Debra G. Silberg, Richard Torstenson, Veronica Miller, Joel E. Lavine, Nathalie Adda, William Baldyga, Rajarshi Banerjee, Cynthia Behling, Sherif Boulos, Gary Burgess, Dania Calboli, Edgar Charles, Rose Christian, Claude Cohen-Bacrie, Doina Cosma-Roman, Claus-Peter Danzer, Ingrid Delaet, Mark Delegge, Nicholas DiProspero, Kathleen Donohue, Laurent Fischer, Emer Fitzpatrick, Michael Fried, David Hagerty, Paula Hale, Keri Hildick, Dean Hum, Khurram Jamil, Lijuan Jiang, Saul Karpen, Matt Kelly, Rohit Kohli, Kattayoun Kordy, Nancy Krieger, Joel Lavine, Lois Lee, Eric Lefebvre, Patricia Lopez, Erica Lyons, Laura Malahias, Sophie Megnien, Peter Mesenbrink, Pansy Minnick, Christine Murray, Tien Nghiem, Nikki Nicholson, Wenjie Pang, Lisa Percival, Dan Peres, Margaret Powell, Dragos Roman, Mark Root, Claire Sampson, Arun Sanyal, Kathleen Schwarz, Star Seyedkazemi, David Shapiro, Reshma Shringarpure, Debra Silberg, Edward Smith, Robert Squires, William Treem, Pamela Vig, Miriam Vos, Mason Yamashita, Michael Zemel, and Liver Forum Pediat Working Grp
- Subjects
medicine.medical_specialty ,MEDLINE ,Gastroenterology ,Severity of Illness Index ,Article ,Drug Development ,Non-alcoholic Fatty Liver Disease ,Internal medicine ,Nonalcoholic fatty liver disease ,Severity of illness ,medicine ,Prevalence ,Humans ,Child ,Clinical Trials as Topic ,Hepatology ,business.industry ,Patient Selection ,Age Factors ,medicine.disease ,Drug development ,Liver ,Human medicine ,business ,Liver pathology - Published
- 2019
3. Su1681 THE HEPATORENAL SYNDROME PATIENT JOURNEY: PORTRAIT OF AN OFTEN-FATAL PATH FOR THOSE WITH LIVER DISEASE
- Author
-
David K. Hayashida, Rita M. Tavares, Xin Huang, Kunal Lodaya, and Khurram Jamil
- Subjects
Pediatrics ,medicine.medical_specialty ,Liver disease ,Portrait ,Hepatology ,Hepatorenal syndrome ,business.industry ,Path (graph theory) ,Gastroenterology ,medicine ,business ,medicine.disease - Published
- 2020
4. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1
- Author
-
Santiago J. Munoz, Kevin M. Korenblat, Howard Paul Monsour, Richard Gilroy, Marie Noëlle Pépin, Yuri Genyk, Andrea Duchini, David A. Sass, Khurram Jamil, Colin Swales, Obaid S. Shaikh, John R. Lake, Kris V. Kowdley, Zeid Kayali, Stevan A. Gonzalez, Alex S. Befeler, Joseph F. Buell, Florence Wong, Terry Box, Samuel H. Sigal, Victor Araya, Mark N. Wong, Michael B. Fallon, Sukru Emre, Adnan Said, Atif Zaman, Paul Y. Kwo, Paul Angulo, Fredric Regenstein, Maria Del Pilar Hernandez, Hugo E. Vargas, Eva Urtasun Sotil, Priya Grewal, David S. Barnes, Marco Olivera-Martinez, Tarek Hassanein, Juan A. Guerrero, Brendan M. McGuire, Eyob Feyssa, David S. Wolf, K. Rajender Reddy, Nathan J. Shores, R. Todd Frederick, Hany Elbeshbeshy, Stephen D. Zucker, Lorenzo Rossaro, Vishal C. Patel, Daniel Ganger, Arun J. Sanyal, Ram Subramanian, Fredric G. Regenstein, Charles D. Howell, Thomas D. Boyer, Jacqueline G. O'Leary, Nikroo Hashemi, Marlyn J. Mayo, Stephen Chris Pappas, Jasmohan S. Bajaj, Michael P. Curry, Michael K. Porayko, Rohit Satoskar, Madhavi Rudraraju, Kirti Shetty, Antonio Sanchez, K. Gautham Reddy, and David Kravetz
- Subjects
Adult ,Liver Cirrhosis ,Male ,Canada ,medicine.medical_specialty ,Hepatorenal Syndrome ,Cirrhosis ,medicine.medical_treatment ,Lypressin ,Renal function ,Kidney ,Kidney Function Tests ,Placebo ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Hepatorenal syndrome ,Albumins ,Internal medicine ,Ascites ,Humans ,Vasoconstrictor Agents ,Medicine ,Renal replacement therapy ,Creatinine ,Hepatology ,business.industry ,Middle Aged ,medicine.disease ,Surgery ,Treatment Outcome ,chemistry ,030220 oncology & carcinogenesis ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,medicine.symptom ,business ,Terlipressin ,medicine.drug - Abstract
Hepatorenal syndrome type 1 (HRS-1) in patients with cirrhosis and ascites is a functional, potentially reversible, form of acute kidney injury characterized by rapid (2 wk) and progressive deterioration of renal function. Terlipressin is a synthetic vasopressin analogue that acts, via vascular vasopressin V1 receptors, as a systemic vasoconstrictor. We performed a phase 3 study to evaluate the efficacy and safety of intravenous terlipressin plus albumin vs placebo plus albumin in patients with HRS-1.Adult patients with cirrhosis, ascites, and HRS-1 (based on the 2007 International Club of Ascites criteria of rapidly deteriorating renal function) were assigned randomly to groups given intravenous terlipressin (1 mg, n = 97) or placebo (n = 99) every 6 hours with concomitant albumin. Treatment continued through day 14 unless the following occurred: confirmed HRS reversal (CHRSR, defined as 2 serum creatinine [SCr] values ≤1.5 mg/dL, at least 40 hours apart, on treatment without renal replacement therapy or liver transplantation) or SCr at or above baseline on day 4. The primary end point was the percentage of patients with confirmed CHRSR. Secondary end points included the incidence of HRS reversal (defined as at least 1 SCr value ≤1.5 mg/dL while on treatment), transplant-free survival, and overall survival. The study was performed at 50 investigational sites in the United States and 2 in Canada, from October 2010 through February 2013.Baseline demographic/clinical characteristics were similar between groups. CHRSR was observed in 19 of 97 patients (19.6%) receiving terlipressin vs 13 of 99 patients (13.1%) receiving placebo (P = .22). HRS reversal was achieved in 23 of 97 (23.7%) patients receiving terlipressin vs 15 of 99 (15.2%) receiving placebo (P = .13). SCr decreased by 1.1 mg/dL in patients receiving terlipressin and by only 0.6 mg/dL in patients receiving placebo (P.001). Decreases in SCr and survival were correlated (r(2) = .882; P.001). Transplant-free and overall survival were similar between groups. A significantly greater proportion of patients with CHRSR who received terlipressin survived until day 90 than patients who did not have CHRSR after receiving terlipressin (P.001); this difference was not observed in patients who did vs did not have CHRSR after receiving placebo (P = .28). There were similar numbers of adverse events in each group, but patients in the terlipressin group had more ischemic events.Terlipressin plus albumin was associated with greater improvement in renal function vs albumin alone in patients with cirrhosis and HRS-1. Patients had similar rates of HRS reversal with terlipressin as they did with albumin. ClinicalTrials.gov no: NCT01143246.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.